Navigation Links
Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists and Collaborators in Nature Biotechnology
Date:3/24/2008

A Published Study Shows the Potential of microRNAs to be Used as Biomarkers for Diagnosing the Primary Tumor Site in Patients With Cancer of Unknown

Primary (CUP) Rosetta Genomics is Currently Developing a Technology That Will be the

Basis of a CUP Diagnostic Test That Will be Submitted for Regulatory

Approval by a CLIA-certified lab in the US in 2008 Approximately 70,000 Patients in the US are Diagnosed With CUP Each Year Only After Several Tests Have Failed to Identify the Origin of the Cancer; Accurate Diagnosis for CUP can be Critical in Determining Optimal Treatment

Decisions

REHOVOT, Israel and JERSEY CITY, New Jersey, March 24 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), announced today that the results of a research study, conducted by its scientists and collaborators and describing the use of microRNAs in accurately identifying tumor origin, have been published in Nature Biotechnology. . The study findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients with cancer of unknown primary (CUP). Rosetta Genomics is currently developing a technology that will be the basis of a CUP diagnostic tests that will be submitted by a CLIA certified lab in the US in 2008..

"Accurately identifying the origin of a metastasis in CUP patients can be critical for determining appropriate treatment, and currently presents a true unmet diagnostic need for patients and physicians," said Amir Avniel, President and CEO of Rosetta Genomics. "This research demonstrates the tremendous potential of microRNAs as e
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
2. ABCs Private Practice Inaccurately Portrays Serious Womens Health Condition
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
7. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
8. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
9. On the road to a new cancer therapy -- starving the tumor
10. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
11. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment b...d (ASX:NEU) has agreed an AU$6.7 mil convertible n...vestor. The private placement was arranged by KTA ...advisor. , New York (PRWE...nvestment bank KTA Capital, LLC ("KTA Capital...
(Date:11/24/2009)..., REYKJAVIK,Iceland,November24/PRNewswire-Fir...nnouncedthatithasreceivednoticefrom,theNasdaqStock...uspendedasofNovember30,2009andaForm25-NSEwillbefil...lremovedeCODE,scommonstock,fromlistingonNasdaq,unl...ficationsPanel.Thecompanyhasfiledsuchanappeal,whic...
(Date:11/24/2009)..., REYKJAVIK,Iceland,November24/PRNewswire-Fir...nnouncedtheapprovalofallofits,"firstday"motionsbyt..."BankruptcyCourt").deCODElastweekfiledavoluntarype...kruptcyCodewiththe,BankruptcyCourt. , Theorde...nue,tooperateitsbusinessduringtheChapter11proceedi...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiB...stration(SFDA)hasapprovedthe,investigationalnewdru...,aninnovativeinsulinformulationtotreatdiabetes.Thi...clinicalstudy. , Diabetesisadisordercharacter...icationsofdiabetesoftenresultinseveremicro-and,mac...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2
...r KOS-1584, HAYWARD, Calif., Oct. 25 Kosan Biosc...ed that Roche and Kosan are,concluding their epoth...ion. The collaborative research, development and,c...er 2002 will terminate,after a transition period, ...hts to its epothilone program and have full contro...
...RTC International Conference, SAN DIEGO, Oct. 25 ...opharmaceutical research and development company,f...idates for the treatment,of cancer and infectious ...,results demonstrating that ANX-514, the company,s...ersensitivity reactions without impacting,pharmaco...
...Inc. (OTC Bulletin Board: NILT.OB) will present at...ence at 10:30 AM EST on Wednesday, November 7th at... Chief Executive Officer of Nile will provide an,o...lopment programs,including data from Nile,s recent...CD-NP, a novel chimeric peptide for the treatment ...
Other Biology Technology:Kosan to Reacquire Epothilone Program From Roche 2Kosan to Reacquire Epothilone Program From Roche 3Kosan to Reacquire Epothilone Program From Roche 4ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 2ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 3ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 4ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 5Nile Therapeutics to Present at the Rodman & Renshaw 9th Annual Healthcare Conference 2
(Date:11/24/2009)...or thousands of years it has been prescribed by tr...lments from headaches and stomach pain to fever an...ewcastle University have been able to scientifical...crenata otherwise known as Brazilian mint. , Te...e team led by researcher Graciela Rocha was able t...
(Date:11/24/2009)...he atomic-level action of a remarkable class of ri...earchers with the Lawrence Berkeley National Labor...ein crystallography beamline at the Advanced Light...oles in gene expression and replication, and are v...ell as infectious agents, such as the human papill...
(Date:11/24/2009)...ambridge, Md. (November 24, 2009) New research on... river ecosystems reveals predictable temporal pat...communities as markers for monitoring climate chan... week in the Proceedings of the National Academy ...ommunities in the six rivers shifted synchronously...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 1iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 13762 1Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 13762 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 13762 3Blood Thinner May Prevent Chemo Related Clots 55837 1Blood Thinner May Prevent Chemo Related Clots 55837 2
...at Rensselaer Polytechnic Institute have discovere...o live. In two recently published papers, the scie...m behind the pathogen that causes cholera. The wor...hogen, while also offering insight into how cells ...ms required to sustain life. , As a single-cell or...
...5th issue of G&D, Dr. Michael Carey (UCLA,s Jo...lend new insight into the mechanism of epigenetic ...sizes that "The study provides a new direction to ...enomena that play a significant role in stem cell ...ach other to turn genes off. " , Although both...
...ew imaging technology, researchers are getting a b...w insects, which have a respiratory system built t...vive for days without it. , The insect respiratory...taking in air as they release carbon dioxide, acco...iversity in Berlin, Germany. This allows them to k...
Other Biology News:Cholera pathogen reveals how bacteria generate energy to live 2Cholera pathogen reveals how bacteria generate energy to live 3Breathing easy: When it comes to oxygen, a bug's life is full of it 2Breathing easy: When it comes to oxygen, a bug's life is full of it 3Breathing easy: When it comes to oxygen, a bug's life is full of it 4
...ntended for users requiring mass detection but not... TOF Mass spectrometer is ideally suited for high ...ance mass analysis. Typical applications include ...tion, micro-satellite DNA characterization and pol...
RAOSMC (R354-05) from European Collection of Cell Cultures (ECACC)
RDF (R106-05) from European Collection of Cell Cultures (ECACC)
...he miVac DNA is an ideal small concentrator for th...l concentrator capable of removing water and organ...ding tubes, microplates, vials and round bottom fl... for the busy lab. ,The built-in special runs...
Biology Products: